CD123: a paradigmatic target for immunotherapeutic treatment modalities
CD123: a paradigmatic target for immunotherapeutic treatment modalities
This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment modalities. CD123, or the interleukin-3 receptor alpha subunit (IL-3R?) is differentially and significantly overexpressed in a large proportion (up to 93 %) of patients with acute myeloid leukemia (AML) and has been identified as a marker of quiescent leukemic stem cells with very low or negligible expression in normal CD34+ progenitor cells. However, CD123 is normally expressed at low levels on some endothelial cells, monocytes, plasmocytoid dendritic cells (pDC), basophils, and myeloid progenitors. This expression profile makes CD123 an attractive surface target for novel antileukemic therapies.
Clinical experience showed that the simple blockade of interleukin-3 signalling by a naked antibody was an insufficient therapeutic strategy which opened the way for generation and devleopment of empowered anti-CD123 immunotherapeutics using emerging novel treatment modalities including:
This report describes and analyzes the
This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment modalities. CD123, or the interleukin-3 receptor alpha subunit (IL-3R?) is differentially and significantly overexpressed in a large proportion (up to 93 %) of patients with acute myeloid leukemia (AML) and has been identified as a marker of quiescent leukemic stem cells with very low or negligible expression in normal CD34+ progenitor cells. However, CD123 is normally expressed at low levels on some endothelial cells, monocytes, plasmocytoid dendritic cells (pDC), basophils, and myeloid progenitors. This expression profile makes CD123 an attractive surface target for novel antileukemic therapies.
Clinical experience showed that the simple blockade of interleukin-3 signalling by a naked antibody was an insufficient therapeutic strategy which opened the way for generation and devleopment of empowered anti-CD123 immunotherapeutics using emerging novel treatment modalities including:
- Fc-engineered antibodies;
- Immunotoxins;
- Antibody-drug conjugates;
- T-cell redirecting bispecific antibodies;
- Chimeric Antigen Receptor (CAR) engineered T-cells.
This report describes and analyzes the
- Target Background & Scientific Rationale
- Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
- Clinical Experience with CD123-Targeted Treatment Modalities
- Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
- Competitive Landscape
- Profiles of Anti-CD123 Immunotherapeutics
- Company Profiles
Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:
Immunotoxins
Naked Antibody
Fc-Engineered Antibodies
Antibody-Drug Conjugates
T-Cell Redirecting Bispecific Antibodies
Anti-CD123 CAR T-Cells
Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:
Immunotoxins
Naked Antibody
Fc-Engineered Antibodies
Antibody-Drug Conjugates
T-Cell Redirecting Bispecific Antibodies
Anti-CD123 CAR T-Cells
Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics